Finding new treatments for NF2 schwannomas
Identification of novel therapeutic combinations for NF2 schwannomas
This study is looking at new ways to treat schwannomas, which are tumors that can grow on nerves in people with neurofibromatosis type 2 (NF2), by testing different combinations of medications in specially designed mice, with the hope of finding effective treatments for patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11009981 on NIH RePORTER |
What this research studies
This research focuses on developing new therapeutic combinations to treat schwannomas associated with neurofibromatosis type 2 (NF2). NF2 is a genetic condition that leads to the growth of benign tumors on nerves, which can cause significant health issues. The researchers are using genetically engineered mouse models to study tumor growth and test potential drug combinations that could halt or reverse tumor progression. The goal is to translate these findings into effective treatments for patients suffering from NF2.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with neurofibromatosis type 2 who are experiencing schwannoma-related symptoms.
Not a fit: Patients without a diagnosis of neurofibromatosis type 2 or those not affected by schwannomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new, effective treatment options for patients with NF2 schwannomas, potentially improving their quality of life.
How similar studies have performed: Other research has shown promise in developing treatments for similar conditions, but this approach is innovative and aims to address a significant unmet need in NF2 treatment.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Clapp, David W — Indiana University Indianapolis
- Study coordinator: Clapp, David W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.